Alzheimer's disease (AD) is the major cause of adult-onset dementia and is characterized in its pre-diagnostic stage by reduced cerebral cortical glucose metabolism and in later stages by reduced cortical oxygen uptake, implying reduced mitochondrial respiration. Using quantitative PCR we determined the mitochondrial DNA (mtDNA) gene copy numbers from multiple groups of 15 or 20 pyramidal neurons, GFAP (+) astrocytes and dentate granule neurons isolated using laser capture microdissection, and the relative expression of mitochondrial biogenesis (mitobiogenesis) genes in hippocampi from 10 AD and 9 control (CTL) cases. AD pyramidal but not dentate granule neurons had significantly 3
human neural stem cells to the neurotoxic fragment Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] , mtDNA copy numbers were not significantly altered. In summary, AD post-mortem hippocampal pyramidal neurons have reduced mtDNA copy numbers.
Mitochondrial biogenesis pathway signaling relationships are disrupted in AD, but are mostly preserved in CTL. Our findings implicate complex alterations of mitochondria-host cell relationships in AD.
Background
Alzheimer's disease (AD) is the most common neurodegenerative disease of adults and the major cause of age-related dementia. Memory loss first appears in the disorder known as "mild cognitive impairment" (amnestic MCI) that progresses into AD dementia at a rate of ~15% per year. Biomarkers of MCI include reduced cerebral glucose accumulation with preserved oxygen uptake and increased brain tissue markers of oxidative stress [1, 2] . Progression into AD dementia is associated with further reductions of cortical glucose accumulation and reduced brain oxygen consumption [1, 2] . These observations suggest that the AD brain may be "starving" metabolically [3] .
Studies of post-mortem tissue support impaired bioenergetic metabolism in AD that may play a role in the degenerative loss of hippocampal and cortical neurons. There is loss of activities of decarboxylase TCA enzyme complexes [2, [4] [5] [6] and reduced mitochondrial respiration, mitochondrial mass and expression of mitochondrial biogenesis (mitobiogenesis) genes in post-mortem AD brain tissue [5, 7] . Individual AD brain neurons have impaired cytochrome oxidase activity histochemically [6] , are populated by deleted mitochondrial DNA (mtDNA) molecules [8] and have reduced expression of nuclear encoded respiratory genes [9] . Loss of cerebral glucose accumulation in MCI and later in AD dementia and direct indicators of impaired mitochondrial function in AD brains could occur from lowered glucose transport, impairment of glycolysis, reduced activities of mitochondrial oxidative decarboxylation in the TCA cycle, impaired mitochondrial respiration, or combinations of these processes.
Mitochondrial respiration involves many proteins encoded both from nuclear and mitochondrial DNA. A complex regulatory system ensures an appropriate coordinated expression from both genomes for both basal respiratory levels or stress-induced upregulation (for review see: [10] [11] [12] [13] ). Nuclear respiratory (transcription) factors 1 and 2 (NRF1 and NRF2) activate transcription of nuclear-encoded respiratory genes and transcription factor A from mitochondria (TFAM). TFAM initiates transcription of the mitochondrial-encoded respiratory genes and has a role in maintaining the mtDNA copy number and stabilizing the mtDNA. Peroxisome proliferator-activated receptor gamma coactivator 1α (PGC1α) is a coactivator for many mitobiogenesis-associated transcription factors including NRF1, NRF2 and estrogen-related receptor α (ERRα, associated with fatty acid oxidation). PGC1α plays a key role in responding to environmental changes, through both post-translational modifications and increased expression, to turn on mitobiogenesis [14] . Although the exact mechanism of how PGC1α upregulates expression of the nuclear transcription factors is not clear, increased expression of NRF1 and NRF2 and subsequent increased expression of TFAM are observed when PGC1α is overexpressed [15] . Additionally, PGC1α does bind with NRF1, NRF2 and ERRα and co-activates expression of their target genes resulting in significantly increased mitobiogenesis resulting in the label of the "master regulator".
The present study examines in more detail the status of mtDNA and the expression levels of select mitobiogenesis genes from post-mortem AD and and 4 caps/case we could minimize the variability that occurs due to the 10 µm slice being in different planes of each cell (Supplemental Figure 2 ). Caps were extracted overnight at 65 o C with 50µl tris buffered proteinase K for DNA extraction [17] . The proteinase K was heat inactivated and 200µl TE was added.
Multiplex qPCR was used to determine gene copy number for 4 genes around the mitochondrial genome (12S rRNA, ND2, ND4 and COX III) from LCM isolated cells. The mtDNA copy number was determined/cap of 15 or 20 cells by comparing to a standard curve of circular human mtDNA run on the same plate.
The mtDNA standards were prepared as described previously [18] . Since there was minimal variability between the 4 genes, the average of the 4 genes was used to estimate mtDNA copy number/LCM cap. Primer and probe sequences are listed in the Supplemental Table. Relative gene expression from whole hippocampal tissue: Whole tissue cDNA was analyzed for expression of nuclear encoded mitobiogenesis genes. Relative expression of PGC-1α, NRF1, NRF2, TFAM and ERRα were determined using Sofast EvaGreen (BioRad) qPCR and primers we designed using Beacon designer software. A panel of 6 reference genes was assessed using Sofast EvaGreen qPCR to determine 3 with the least variability across all cases. GAPDH, 14-3-3z and CYC-1 were selected with GeNorm analysis in qbase PLUS (Biogazelle) and their geometric means in each cDNA sample were used to normalize relative expression of the mitobiogenesis regulatory genes. All EvaGreen qPCR experiments included a human fetal brain cDNA standard curve for assessing relative expression of each gene. Melt curves were run with each qPCR to ensure only a single species was being amplified. Specific primer sequences used are in the Supplemental Table. Aß elisa: Slices were dissolved in 5M guanidine, 50mM tris (pH 8.0) plus protease inhibitor cocktail (Calbiochem, set III). Protein concentrations were determined using the Pierce BCA protein assay with BSA as the standard.
Samples were diluted with 0.1M phosphate (pH7.4) to achieve 1mg/ml.
Sandwich elisas were analyzed using 50µl of each sample in duplicate following the manufacturer's protocol (Invitrogen). Most AD cases were much higher than the CTLs, so they were re-analyzed shortening the time of the horseradish peroxidase visualization step so the high end of the standard curve and those were diluted to 2 mM in water and aliquots stored frozen. 72 hours before treatment aliquots were placed at 37°C to aggregate [19] . 35 mm dishes of 90% confluent H9 NSCs were treated with 10 uM aggregated Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] (Fig. 1A ) are shifted to a larger proportion being less than 100% compared to CTL (Fig. 1B) indicating significantly decreased mtDNA copy numbers in hippocampal pyramidal neurons from AD cases (p=0.0086, non-parametric KolmogorovSmirnov test). Mitochondrial DNA copy numbers in glia from AD (Fig. 1C) were not statistically significantly different from CTL (Fig. 1D) , although there was a trend towards significance (p=0.0899, non-parametric Kolmogorov-Smirnov test).
Mitochondrial DNA copy numbers in dentate granule cells were not significantly different in AD compared to CTL (Fig. 1 E,F) . A t-test of the raw values of the mtDNA copy numbers from hippocampal pyramidal neurons also indicated a statistically significant decrease of 17% (p=0.0475) in AD compared to CTL (data not shown).
mtDNA copy number in CTL but not in AD pyramidal neurons correlates with cDNA levels of mitobiogenesis factors NRF2, ERRα, NRF1 and TFAM.
To determine if the decreased mtDNA copy numbers in AD pyramidal neurons were related to the relative expression of the mitobiogenesis genes, we extracted total RNA from frozen sections of the same tissue block used for the specific cell isolation and generated cDNA using random hexamer priming. The relative expression of each gene was normalized to reference genes with the least variability across all samples (See Methods). Figure 2 shows the relatively linear relationships among levels of pyramidal neuron mtDNA gene copy numbers (average/case) and the reference-gene normalized expressions of the mitobiogenesis factors NRF2, NRF1, ERRα and TFAM in CTL (Fig. 2B, D, F, H ), but not AD pyramidal neurons (Fig. 2 A, C mtDNA copy number does not correlate to Aβ (1-42) levels. To determine if Aβ 1-42 levels were related to the decreased mtDNA copy numbers in AD pyramidal neurons we prepared whole tissue homogenates from the same tissue blocks used to isolate specific cell types and analyzed for Aβ 1-42 levels using a sandwhich elisa. Figure 4 shows the lack of correlation of mtDNA gene levels in isolated pyramidal neurons, GFAP (+) astrocytes and dentate gyrus granule cells Figure 5) . The lack of correlations in the AD cases may be skewed by the one AD case with low Aβ levels. 
Exposure of human H9 neural precursor cells to neurotoxic Aβ

Discussion
In our postmortem AD hippocampi we found that mtDNA gene copy numbers were significantly reduced in surviving pyramidal neurons compared to identical cell types in CTL hippocampi. This is consistent with the observation of reduced mtDNA copy numbers in whole hippocampi [7] and cortex [20] from AD cases. However, Hirai, et al., [21] using in situ hybridization detected increased mtDNA in hippocampal pyramidal neurons from AD cases compared to CTL; from EM photos they determined many of these were in lipofuscin vacuoles and are likely from degrading mitochondria. Additionally, they did not detect mtDNA differences in the glia or granule cells by in situ hybridization, which is consistent with our observations in those cell types. They also comment that using PCR techniques, they did not detect an overall difference in mtDNA in AD compared to control tissue. Our cells were isolated by laser capture and only intact cells were selected, which could explain the difference between our study and their study.
Another factor that could be contributing to the decreased mtDNA copy number in AD in our study is that the control cases were younger (~16yr) than the AD cases. Our group has previously demonstrated dramatically decreased (~90% loss) mtDNA copy numbers in whole brain tissue from 21 month old mice compared to 5 month old mice [22] . Since our samples were isolated from selected intact cells, we would not expect as dramatic a difference due to age as is observed in whole tissue studies. A comparison of mtDNA copy number/LCM cap or mitobiogenesis genes versus age revealed no correlation in either AD cases or CTL cases in our cohort of samples (Supplemental Figure 6 ).
Additionally, unknown factors about the individual's pre-mortem status, such as medications they may have been on, could also have affected the mtDNA copy number values we determined.
Recently, cell-free mtDNA copy numbers in cerebral spinal fluid (CSF) from AD subjects, asymptomatic at risk subjects and pre-symptomatic subjects with a pathogenic PSEN1 mutation have been shown to be markedly reduced compared to age matched control subjects, non-pathogenic PSEN1 mutation family members, or individuals with a different dementia pathology (FTLD),
These findings indicate that the reduced mtDNA copy numbers both occur prior to clinical symptoms appearing in AD and appear to be selective for AD dementia [23] . The same authors reported that levels of mtDNA were reduced in cortical neurons derived from a transgenic (APP/PS1) mouse model of familial AD. They conclude that reduced CSF mtDNA levels appear to be a robust biomarker for pre-AD dementia. They also suggest that the significant loss of mtDNA copy numbers we observed in hippocampal pyramidal neurons and nearly significant loss of mtDNA in GFAP(+) astrocytes have clinical correlates in CSF and may represent early pathogenic events in AD.
Previous studies from our group have demonstrated decreased mRNA expression of mitochondrial encoded genes in cortical AD tissue homogenates from the same tissue sources used in the present study [5] . Decreased mRNA expression of many of the mitobiogenesis genes (PGC1α, NRF1, TFAM, POLγ and PPRC1) were also detected in the cortical AD tissue homogenates compared to CTL [5] . In hippocampal tissue homogenates from AD cases, Sheng, et al., [7] observed decreased mitobiogenesis protein levels compared to control tissue (PGC1α, NRF1, NRF2α, NRF2β and TFAM). Subsequently, when they stably knocked down PGC1α in a cell culture line, they observed the expected decreases in protein levels as well as reduced mtDNA levels relative to nuclear DNA levels by about 50% [7] , supporting the regulatory hierarchy of PGC1α upregulating NRF1 and NRF2 leading to increased levels of TFAM and subsequently increased mtDNA levels. Our decrease in mtDNA copy number in AD cases was not quantitated the same way as Sheng, et al. [7] and our decreased AD pyramidal neuron mtDNA copy number was not as dramatic as in their cell culture. Our results, obtained from laser-captured, postmortem AD pyramidal neurons complement those Sheng, et al., [7] obtained in cell culture.
We also observed a trend towards decreased mtDNA copy number in laser-captured GFAP(+) glia. Even though it only approached statistical significance, it does demonstrate that the glia, while not thought to be affected in AD, may in fact also be metabolically impaired and contribute to the deficits other groups observe in whole tissue homogenates. Additionally, we observed no difference in mtDNA copy number in dentate gyrus granule cells, suggesting that they may not be bioenergetically altered in AD, and adding cell specificity to our tissue from autopsy cases the hierarchy of mitobiogenesis regulation appears to be intact. However, in AD tissue this correlation was missing, supporting the idea of impaired mitobiogenesis in AD as purported by others [5, 7] . Microarray analysis of LCM isolated hippocampal pyramidal neurons from AD cases has shown decreased expression of nuclear encoded respiratory genes, which is also consistent with impaired mitobiogenesis [9] .
We also found in CTL, but not AD, hippocampal cDNA significant linear relationships among expression of the "master" mitobiogenesis regulator PGC-1α
and multiple downstream mitobiogenesis factors it co-activates (NRF2 and ERRα) and a trend towards significance in others (NRF1) [11, 12] . Due to the heterogeneity of human samples, had our n values been larger, we may have achieved better correlations between all the mitobiogenesis genes expression levels. These studies also support an intact mitobiogenesis hierarchy in CTL autopsy tissue that is lost in AD tissue. Future studies will examine this relationship specifically in pyramidal neurons.
A significant correlation between PGC1α and two key metabolism related proteins (pyruvate dehydrogenase A1 and complex III subunit UQCRH) has been demonstrated in skeletal muscle biopsies from diabetics (type II), and those with and without a family history of diabetes mellitus [24] . In a model of muscle disuse atrophy, Cassano, et al., [25] several groups [5, 7] . Speculation as to potential mechanisms of mitobiogenesis disruption would incorporate many potential etiologies and is beyond the scope of this discussion. Future studies will investigate the potential role epigenetic regulation may be playing.
While some studies correlate Aβ 1-42 levels with AD pathology, we found no correlation of Aβ 1-42 levels to the mtDNA copy number reductions in hippocampal pyramidal neurons, glia or dentate granule cells from AD cases, which is similar to what our group found previously in cortical tissue homogenates [5] . Supplemental Figure 6 . Correlation between mtDNA copy number and relative mitobiogenesis gene expression from AD and CTL cases vs age.
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